The Latest News from Vascular Therapies

Vascular Therapies to Participate in the SVB Leerink 9th Annual Global Healthcare Conference

CRESSKILL, NJ (Feb.11, 2020) – Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced that the company will participate in the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27, 2020, in New York, NY.

Chief Executive Officer, John McDermott, is scheduled to present on Tuesday, February 25, at 1:30 p.m. ET.

PDF iconRead full release

Vascular Therapies Completes Upsized $17.3 Million Private Financing

Company funded through 2020. Topline Phase 3 results for Sirogen expected to be announced in Q2 2020

CRESSKILL, NJ (Jan.28, 2020)– Vascular Therapies, a clinical-stage biopharma company focused on improving vascular access outcomes in patients with kidney disease, today announced the closing of an upsized $17.3 million private financing. The financing comprised existing and new investors, and was increased from an originally targeted $15 million up to $17.3 million, based upon interest from new investors, including a strategic foreign healthcare company.

PDF iconRead full release

Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease

CRESSKILL, NJ (Sep. 5, 2019)–Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease. Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC Medical Group in Columbia, South Carolina presented preliminary results from the company’s clinical development program at the recent Eastern Vascular Society Meeting in Pittsburg, Pennsylvania.

PDF iconRead full release

Vascular Therapies Announces Completion of Enrollment in the ACCESS Study, a U.S. Phase III Clinical Trial

CRESSKILL, NJ (Aug. 19, 2019)–Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced completion of enrollment in its US Phase III prospective randomized, multicenter, clinical study (ACCESS Trial).

PDF iconRead full release

Vascular Therapies Appoints John McDermott as Chief Executive Officer

CRESSKILL, NJ (January 15, 2019) –Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease today announced the appointment of John McDermott as the Company’s Chief Executive Officer.

PDF iconRead full release